Sentence examples for severe chf from inspiring English sources

Since exacerbation of chronic heart failure (CHF) has been reported with TNF inhibitors, however, it has been recommended that adalimumab be avoided in patients with severe CHF (class III or IV) and discontinued in those with mild disease during a CHF exacerbation.

Following development of severe CHF, both noradrenaline and phenylephrine could produce a greater maximum tension and a shift of the resultant concentration-effect curve to the left compared to the curves seen before the development of CHF.

METHODS AND RESULTS: Soluble levels by ELISA were prospectively determined in patients with severe CHF (n = 37) and correlated to etiology and antecedent aspirin use, and compared with 14 healthy control subjects.

CONCLUSIONS: Despite long-term aspirin therapy and independently of the etiology of the disease, soluble PECAM-1 and osteonectin were elevated in the majority of patients with severe CHF, suggesting platelet-endothelial activation.

In so doing, we learned that while CHF patients did not exhibit higher levels of total or early apoptotic progenitors than controls, the more severe CHF patients exhibited elevated numbers of late apoptotic progenitors compared to those with less severe CHF.

However, all available data confirm the existence of relationships between high plasma big-ET-1 and poor outcome in patients with CHF [27], [28], [29], [31], also in those with severe CHF [3], [30], [32].

The prognostic significance of serum magnesium concentration in CHF subjects is currently under investigation, although in a retrospective study of subjects with moderate-to-severe CHF, an inverse correlation was noted between mortality and plasma magnesium [ 77].

However, preliminary results of a study of CCC patients with moderate-to-severe CHF by Bestetti et al. showed that only 37% of the patients tolerated carvedilol after the inhibition of the renin-angiotensin system with high doses of ACEI [ 26].

To date, the symptoms, care needs, caregiver burden, end-of-life care treatment preferences and communication needs of patients with very severe COPD, CHF or CRF remain unknown.

Patients with moderate to severe COPD, CHF or CRF have been shown to suffer from exercise intolerance, muscle weakness and abnormal changes in body composition, irrespective of the degree of primary organ failure.

To date, the symptoms, care needs, caregiver burden, end-of-life care treatment preferences and end-of-life care communication of patients with very severe COPD, CHF or CRF have been studied scarcely.